Plasma Protein Kallikrein-14 Strongly Predicts Pronounced Chromogranin A (CgA) Response in Small Intestinal Neuroendocrine Tumor (NET) Patients after Somatostatin Analog (SSA) Treatment: The Nordic EXPLAIN Biomarker Study
Introduction: Predicting treatment response at an early stage in the treatment algorithm for NET is highly desirable.
Aim(s): To investigate 92 putative cancer-related proteins in plasma at the time of diagnosis and after 6 months of treatment in an attempt to explore new predictive biomarkers.
Materials and methods: One hundred small intestinal NET patients from 16 Nordic centers were prospectively followed. Blood samples were obtained before start of treatment, and 6 (±3) months after initiation of treatment. Plasma samples were analysed with Olink Proseek Multiplex Oncology II panel. Chromogranin A (CgA) was analysed centrally at Akademiska Lab Uppsala (NEOLISA Euro Diagnostica). Treatment response was analysed using a logistic regression model adjusted for the baseline CgA value and the baseline value of the biomarker.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Kjellman M
Keywords: Plasma Protein Biomarker,
To read the full abstract, please log into your ENETS Member account.